公开(公告)号：IL290004D0

公开(公告)日：2022-03-01

申请号：IL29000422

申请日：2022-01-20

Applicant: ASPEN PARK PHARMACEUTICALS INC

IPC: A61K31/138 ,  A61P19/08 ,  A61P19/10 ,  A61P43/00

Abstract: This invention provides: 1) a method of treating androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer: 2) a method of preventing androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer: 3) a method of suppressing or inhibiting androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/ or hot flashes in a male subject suffering from prostate cancer: and 4) a method of reducing the risk of developing androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/ or hot flashes in a male subject suffering from prostate cancer, by administering to the subject a pharmaceutical composition comprising cis-clomiphene or a pharmaceutically acceptable salt thereof.

公开(公告)号：PL3171866T3

公开(公告)日：2021-04-06

申请号：PL15824708

申请日：2015-07-23

Applicant: ASPEN PARK PHARMACEUTICALS INC

Inventor： STEINER MITCHELL ,  FISCH HARRY

IPC: A61K31/137 ,  A61K31/138 ,  A61P9/00 ,  A61P19/08 ,  A61P19/10 ,  A61P43/00

公开(公告)号：LT3171866T

公开(公告)日：2020-12-28

申请号：LT15824708

申请日：2015-07-23

Applicant: ASPEN PARK PHARMACEUTICALS INC

Inventor： STEINER MITCHELL ,  FISCH HARRY

IPC: A61K31/137 ,  A61K31/138 ,  A61P9/00 ,  A61P19/08 ,  A61P19/10 ,  A61P43/00

公开(公告)号：AU2015292519B2

公开(公告)日：2020-09-03

申请号：AU2015292519

申请日：2015-07-23

Applicant: ASPEN PARK PHARMACEUTICALS INC

Inventor： STEINER MITCHELL ,  FISCH HARRY

IPC: A61K31/137 ,  A61K31/138 ,  A61P19/10

Abstract: This invention provides: 1) a method of treating androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer; 2) a method of preventing androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer; 3) a method of suppressing or inhibiting androgen- deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/ or hot flashes in a male subject suffering from prostate cancer; and 4) a method of reducing the risk of developing androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/ or hot flashes in a male subject suffering from prostate cancer, by administering to the subject a pharmaceutical composition comprising cis-clomiphene or a pharmaceutically acceptable salt thereof.

公开(公告)号：CA3023106A1

公开(公告)日：2017-11-09

申请号：CA3023106

申请日：2017-05-04

Applicant: ASPEN PARK PHARMACEUTICALS INC

Inventor： BARNETTE K GARY ,  STEVENS RUTH E ,  PHELPS KENNETH V ,  GOLD LYNN

IPC: A61K9/16 ,  A61K31/18 ,  A61K31/473 ,  A61K45/06

Abstract: The present invention relates in certain embodiments to a controlled release formulation, especially a sachet, comprising a unit dosage of a dry powder of tamsulosin or a pharmaceutically acceptable salt thereof in a controlled release matrix and to methods of making and using such formulation. The controlled release formulation is beneficial in the treatment of benign prostatic hyperplasia (BPH), particularly in those patients suffering from dysphagia. The controlled release formulation is easily dispersed in water or other suitable liquid, and so solves the problem of dysphagia, thereby improving patient compliance in that targeted patient population, yet the controlled release formulation has a release profile in a patient on an empty stomach similar to FLOMAX® ((R)-5-(2-{[2-(2-Ethoxyphenoxy)ethyl]amino}propyl)-2-methoxybenzene-1-sulfonamide hydrochloride) taken 30 minutes after a meal, but does not exhibit the FLOMAX® tablet food effect, thereby improving dosage form administration flexibility.

公开(公告)号：HRP20201726T1

公开(公告)日：2021-01-08

申请号：HRP20201726

申请日：2020-10-26

Applicant: ASPEN PARK PHARMACEUTICALS INC

Inventor： STEINER MITCHELL ,  FISCH HARRY

IPC: A61K31/137 ,  A61K31/138 ,  A61P9/00 ,  A61P19/08 ,  A61P19/10 ,  A61P43/00

公开(公告)号：AU2017260505A1

公开(公告)日：2018-12-06

申请号：AU2017260505

申请日：2017-05-04

Applicant: ASPEN PARK PHARMACEUTICALS INC

Inventor： BARNETTE K GARY ,  STEVENS RUTH E ,  PHELPS KENNETH V ,  GOLD LYNN

IPC: A61K9/16 ,  A61K31/18 ,  A61K31/473 ,  A61K45/06

Abstract: The present invention relates in certain embodiments to a controlled release formulation, especially a sachet, comprising a unit dosage of a dry powder of tamsulosin or a pharmaceutically acceptable salt thereof in a controlled release matrix and to methods of making and using such formulation. The controlled release formulation is beneficial in the treatment of benign prostatic hyperplasia (BPH), particularly in those patients suffering from dysphagia. The controlled release formulation is easily dispersed in water or other suitable liquid, and so solves the problem of dysphagia, thereby improving patient compliance in that targeted patient population, yet the controlled release formulation has a release profile in a patient on an empty stomach similar to FLOMAX® ((R)-5-(2-{[2-(2-Ethoxyphenoxy)ethyl]amino}propyl)-2-methoxybenzene-1-sulfonamide hydrochloride) taken 30 minutes after a meal, but does not exhibit the FLOMAX® tablet food effect, thereby improving dosage form administration flexibility.

公开(公告)号：MX2018010286A

公开(公告)日：2018-09-27

申请号：MX2018010286

申请日：2017-02-23

Applicant: ASPEN PARK PHARMACEUTICALS INC

Inventor： HARRY FISCH ,  MITCHELL STEINER

IPC: A61K31/138 ,  A61K31/225

Abstract: La presente invención se relaciona con una forma de dosificación oral farmacéutica, que comprende (A) clomifeno trans o una sal farmacéuticamente aceptable del mismo y (B) clomifeno cis o una sal farmacéuticamente aceptable del mismo, en donde (i) la relación de (A) : (B) en la forma de dosificación es de aproximadamente 70:30; (ii) la cantidad de (A) en la forma de dosificación es de aproximadamente 12.5 mg o aproximadamente 25 mg; y (iii) la cantidad de (B) en la forma de dosificación es menor de 15 mg. La forma farmacéutica de dosificación oral es útil para tratar el hipogonadismo secundario en los hombres y minimizar ciertos efectos secundarios de los fármacos antiestrogénicos, como deterioro cognitivo, sofocos y pérdida ósea, osteoporosis y fracturas esqueléticas.

公开(公告)号：AU2015292519A1

公开(公告)日：2017-02-02

申请号：AU2015292519

申请日：2015-07-23

Applicant: ASPEN PARK PHARMACEUTICALS INC

Inventor： STEINER MITCHELL ,  FISCH HARRY

IPC: A61K31/137 ,  A61K31/138 ,  A61P19/10

Abstract: This invention provides: 1) a method of treating androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer; 2) a method of preventing androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer; 3) a method of suppressing or inhibiting androgen- deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/ or hot flashes in a male subject suffering from prostate cancer; and 4) a method of reducing the risk of developing androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/ or hot flashes in a male subject suffering from prostate cancer, by administering to the subject a pharmaceutical composition comprising cis-clomiphene or a pharmaceutically acceptable salt thereof.

公开(公告)号：RU2725086C2

公开(公告)日：2020-06-29

申请号：RU2017105837

申请日：2015-07-23

Applicant: ASPEN PARK PHARMACEUTICALS INC

Inventor： STEINER MITCHELL ,  FISCH HARRY

IPC: A61P19/10 ,  A61K31/138 ,  A61P35/00

Abstract: Изобретениеотноситсяк медицинеи можетбытьиспользованодляостановки, ингибированияилиуменьшениярискаприливову пациентамужскогопола, проходящегоандрогеннуюдепривационнуютерапиюдлялеченияракапредстательнойжелезы. Дляэтогопациентувводятэффективноеколичествафармацевтическогосостава, содержащегоцис-кломифенилиегофармацевтическиприемлемуюсольи менее 10% масс. транс-кломифенаилиегофармацевтическиприемлемойсоли. Изобретениеобеспечиваетуменьшениеприливовприпроведенииандрогеннойдепривационнойтерапииу пациентамужскогопола, страдающегоракомпредстательнойжелезы. 10 з.п. ф-лы, 2 пр.